John R Pettersson

Dr. John R Pettersson


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HCHaarin Chun
Haarin Chun
JPJohn R Pettersson
John R Pettersson
SSSvetlana A. Shestopal
Svetlana A. Shestopal
WWWells Wu
Wells Wu
EMEkaterina S. Marakasova
Ekaterina S. Marakasova
ASAndrey G Sarafanov
Andrey G Sarafanov
Background Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIIIFT) unable to bind von Willebrand factor (VWF) and reported to lack activity. Due to loss of function(s), FVIIIFT can be defined as a product‐related impurity, whose properties and levels in rFVIII products should be investigated. Objective To isolate and characterize the FVIIIFT fraction in rFVIII products. Methods Protein fractions unable (FVIIIFT) and able (FVIIIEL) to bind VWF were isolated from rFVIII products (FVIIITP) using Immobilized VWF Affinity Chromatography (IVAC) and characterized by gel electrophoresis, immunoblotting, FVIII activity test, surface plasmon resonance, mass spectrometry, and for plasma clearance in mice. Results and Conclusions A robust IVAC methodology was developed and applied for analysis of ten rFVIII products marketed in the USA. FVIIIFT was found at various contents (0.4–21.5%) in all products. Compared to FVIIIEL, FVIIIFT had similar patterns of polypeptide bands by gel electrophoresis, but lower functional activity. In several representative products, FVIIIFT was found to have reduced sulfation at Tyr1680, important for VWF binding, decreased interaction with a low‐density lipoprotein receptor related protein 1 (LRP1) fragment, and faster plasma clearance in mice. These findings provide basic characterization of FVIIIFT and demonstrate a potential for IVAC to control this impurity in rFVIII products to improve their efficacy in therapy of Hemophilia A.


23 March 2018 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
SDSourav Kumar Dey
Sourav Kumar Dey
JPJohn R Pettersson
John R Pettersson
ATAndrea Z. Topacio
Andrea Z. Topacio
SDSubha R. Das
Subha R. Das
Linda A. PeteanuLinda A. Peteanu
Linda A. Peteanu

Verified
Journal Article
Open access
PDF file
SSSvetlana A Shestopal
Svetlana A Shestopal
LPLeonid Parunov
Leonid Parunov
POPhilip Olivares
Philip Olivares
HCHaarin Chun
Haarin Chun
MOMikhail Ovanesov
Mikhail Ovanesov
ASAndrey G Sarafanov
Andrey G Sarafanov
Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (VL and VH) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (FVIII) was shown to inhibit major FVIII functions and is useful in FVIII research. We aimed to investigate the properties of iKM33 enabled with protease-dependent disintegration. Three variants of iKM33 bearing thrombin cleavage sites within the linker were expressed using a baculovirus system and purified by two-step chromatography. All proteins retained strong binding to FVIII by surface plasmon resonance, and upon thrombin cleavage, dissociated into VL and VH as shown by size-exclusion chromatography. However, in FVIII activity and low-density lipoprotein receptor-related protein 1 binding assays, the thrombin-cleaved iKM33 variants were still inhibitory. In a pull-down assay using an FVIII-affinity sorbent, the isolated VH, a mixture of VL and VH, and intact iKM33 were carried over via FVIII analyzed by electrophoresis. We concluded that the isolated VL and VH assembled into scFv-like heterodimer on FVIII, and the isolated VH alone also bound FVIII. We discuss the potential use of both protease-cleavable scFvs and isolated Fv subunits retaining high affinity to the antigens in various practical applications such as therapeutics, diagnostics, and research.